Abpro Holdings, Inc.

Abpro Holdings, Inc., trading under the ticker ACAB, is a biopharmaceutical company that reached public markets through a SPAC transaction and operates in the healthcare and life sciences sector, focused on antibody-based therapeutics. The company filed an 8-K current report with the SEC on October 14, 2025, under accession number 0001213900-25-098341, signaling a reportable corporate event to shareholders and regulators. As of the filing date, Abpro Holdings remains an active reporting company subject to Exchange Act obligations. For full filing history, deal terms, sponsor details, and real-time status tracking on ACAB and hundreds of other SPAC-related issuers, sign up for a SpacDesk account at spacdesk.com.